9th Congress of the European Academy of Paediatric Societies
October 7-11 2022, Barcelona and online
|
ESWI Airborne: Meet the Members
Using mathematical modelling to predict virus evolution and inform pandemic response
The dynamic interplay between epidemiological research, virus evolution, and mathematical modelling is skilfully described by Dr Colin Russell, Professor of Applied Evolutionary Biology and ESWI Board Member.
A Policy brief from the NCD Alliance, the International Diabetes Federation and the World Heart Federation
Pressure Points: Call for simultaneous action on diabetes and hypertension for more resilient health systems
Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model
In this human infection challenge pilot study, adults aged 18–55 years and 60–75 years were assessed for enrolment using protocol-defined inclusion and exclusion criteria.
Good practices: Diabetes Australia influenza and diabetes social media campaign
Stay well and stay out of hospital. Be prepared. Get your annual flu shot.
|
ESWI Airborne: Meet the Members
A mucosal perspective on pandemics
"Learn about the fascinating field of mucosal immunology, vaccine effectiveness, and the role of face-mask protection not from virus particles but “spiticles and snoticles”. Dr Peter Openshaw, ESWI Board Member and Professor of Experimental Medicine, ...
World Influenza Conference
September 17-18 2022, Shenzen China - Virtual
|
ESWI Airborne: Meet the Members
Flu shots for children? Why this should be more on the radar
ESWI Board Member Terho Heikkinen, Professor in paediatrics at the University of Turku in Finland talks about paediatric infectious diseases. Learn about why the flu shot is to be recommended in children.
New study: People with Diabetes are at Increased Risk of Flu Complications
Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial
High-dose influenza vaccines provide better protection against influenza infection than standard-dose in persons aged 65 years and above.
